Clinical Starter Packs

Curated starting points for high-yield specialties

Each pack brings together a key guideline, a current trial, a Drug Science explainer, and a relevant education item so clinicians can get oriented fast.

6 specialties 4 content pillars per pack Open clinical learning

Starter Packs

Use these as orientation pages for a topic area, then continue into the full specialty hub, Trial Radar, Drug Science and education library.

Diabetes / Metabolic

Key Guideline

Insulin efsitora alfa for treating type 2 diabetes

Insulin efsitora alfa is recommended as a treatment option for type 2 diabetes and should be considered within NICE guidance…

View guideline →

Trial Radar

A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity

WVE-007 is a new injectable weight-loss drug being tested for safety and effectiveness in overweight and obese adults, with and…

View trial →

Drug Science

HMG-CoA Reductase — Statins

HMG-CoA Reductase — Statins is a clinically relevant Drug Science explainer.

Open explainer →

Education

NICE NG28: Type 2 Diabetes in Adults — 2024 Update

Apply NICE NG28 updates to type 2 diabetes treatment sequencing, including when SGLT2 inhibitors or GLP-1 receptor agonists should be…

Start learning →

📰

Latest Clinical Brief Weekly type 2 diabetes jab could replace daily injections

Explore specialty hub Follow this specialty

Cardiology / Cardiovascular

Key Guideline

Finerenone for treating chronic heart failure with preserved or mildly reduced ejection fraction

Finerenone is recommended as an option for chronic heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) and can…

View guideline →

Trial Radar

Efficacy and Safety of a Nitric Oxide Generating Dressing for Diabetic Foot Ulcers (ONWARD)

Real world evidence study on the performance and safety of a nitric oxide generating dressing on the treatment of diabetic…

View trial →

Drug Science

HMG-CoA Reductase — Statins

HMG-CoA Reductase — Statins is a clinically relevant Drug Science explainer.

Open explainer →

Education

Cardiovascular Risk Reduction — Latest Evidence 2024

Use QRISK3 and clinical risk factors to identify patients who need lipid-lowering intensification.

Start learning →

📰

Latest Clinical Brief Inside Health

Explore specialty hub Follow this specialty

Respiratory / COPD / Asthma

Key Guideline

XVIVO Perfusion System (ex-situ machine perfusion) for assessing and reconditioning marginal lungs for transplantation: early-use assessment

XVIVO Perfusion System enables ex-situ assessment of marginal donor lungs before transplantation, allowing objective evaluation of organ viability and function…

View guideline →

Trial Radar

A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer’s Disease

What is being tested: SAR448851, a novel once-daily oral medication, is being evaluated in a randomized, placebo-controlled Phase 2 trial…

View trial →

Drug Science

CFTR Modulation

CFTR Modulation is a clinically relevant Drug Science explainer.

Open explainer →

Education

NICE NG185: COVID-19 Rapid Guideline — Long-term Effects

Distinguish ongoing symptomatic COVID-19 from post-COVID-19 syndrome using NICE NG185 definitions.

Start learning →

📰

Latest Clinical Brief ‘Wildly unfair that my husband and I pay £4k a year for ADHD treatment’

Explore specialty hub Follow this specialty

Oncology

Key Guideline

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more lines of anti-HER2 treatment

Trastuzumab deruxtecan is recommended as an option for HER2-positive unresectable or metastatic breast cancer only after 1 or more prior…

View guideline →

Trial Radar

A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma

This is a multi-center, open label, phase II study of tebentafusp in patients with unresectable or metastatic clear cell sarcoma…

View trial →

Drug Science

BRAF/MEK Pathway — Melanoma

BRAF/MEK Pathway — Melanoma is a clinically relevant Drug Science explainer.

Open explainer →

Education

Coming into focus

We’re still building this layer for Oncology.

📰

Latest Clinical Brief Wellbeing support demand for cancer patients grows

Explore specialty hub Follow this specialty

Rheumatology

Key Guideline

Osteoporosis: risk assessment

Use the FRAX tool or DXA scan results to stratify fracture risk in adults aged 50+ with risk factors (prior…

View guideline →

Trial Radar

An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Study tested bimekizumab drug levels and safety in children with inflammatory arthritis conditions.

View trial →

Drug Science

IL-6 Signalling

IL-6 Signalling is a clinically relevant Drug Science explainer.

Open explainer →

Education

JAK Inhibitors: Updated Safety Signals, Patient Selection and Post-ORAL Surveillance

Recorded webinar focused on JAK inhibitors in rheumatology and immune-mediated inflammatory disease.

Watch webinar →

📰

Latest Clinical Brief ‘I’ve never been this good’ – revolutionary immune reset puts lupus in remission

Explore specialty hub Follow this specialty

Infectious Disease

Key Guideline

Transvenous embolisation for spontaneous intracranial hypotension caused by a cerebrospinal fluid–venous fistula

Consider transvenous embolisation in patients with spontaneous intracranial hypotension confirmed to have a cerebrospinal fluid–venous fistula, as it offers a…

View guideline →

Trial Radar